Rafael Holdings, Inc. Class B Common Stock (RFL) Stock Price
RFLStock
$1.39+4.51%52W
Market Cap$72.28M
P/E—
PEG Ratio—
Div yield—
Beta0.67
RFL Share Price Chart
Favorite Metrics
Price vs S&P 500 (26W)-1.31%
Price vs S&P 500 (4W)-29.17%
VGM Score40.77
Industry Peers — Pharmaceuticals(574)
| Symbol | Value Score | Growth Score | Momentum Score | P/S Ratio (TTM) | Revenue Growth TTM (YoY) | Gross Margin (TTM) | EPS Growth (5Y) | Price |
|---|---|---|---|---|---|---|---|---|
RFLRafael Holdings, Inc. Class B Common Stock | D | D | C | 73.8x | 33.9% | 95.1% | — | $1.39 |
| LLYEli Lilly & Co. | D | B | A | 14.9x | 49.6% | 83.4% | 27.6% | $1257.03 |
| JNJJohnson & Johnson | D | C | B | 6.2x | 7.8% | 67.7% | 14.9% | $255.56 |
| ABBVABBVIE INC. | D | C | A | 7.8x | 10.4% | 72.8% | -2.9% | $285.42 |
| MRKMerck & Co., Inc. | D | C | A | 5.4x | 4.6% | 77.3% | 21.2% | $145.95 |
| NVSNovartis AG | C | C | B | 4.9x | 3.3% | 75.0% | 15.3% | $150.62 |
| AZNAstraZeneca PLC | C | B | B | 4.3x | 8.6% | 81.3% | 21.9% | $165.41 |
| ABTAbbott Laboratories | C | C | B | 3.9x | 8.1% | 56.8% | 8.2% | $104.89 |
| NVONovo-Nordisk A/S | B | C | C | 3.5x | 5.6% | 80.7% | 20.7% | $38.83 |
| PFEPfizer Inc. | C | D | A | 2.6x | -0.2% | 74.7% | -3.5% | $29.58 |
| VRTXVertex Pharmaceuticals Inc | D | C | B | 10.1x | 10.2% | 86.0% | 8.3% | $499.74 |
About Rafael Holdings, Inc. Class B Common Stock
Rafael Holdings is a biotechnology company with a lead asset, Trappsol Cyclo, in Phase 3 trials for Niemann-Pick Disease Type C1. The company pursues regulatory approval and commercialization while maintaining a diversified portfolio of clinical and early-stage pharmaceutical and medical device investments. Operations span three segments—healthcare, infusion technology, and real estate—with locations in the United States and Israel.